

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HANGZHOU TIGERMED CONSULTING CO., LTD.**

**杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

**DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication, and considering the recommendation on payment of a final dividend (if applicable).

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, March 18, 2026

*As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.*